For US HealthCare Professionals

NOW AVAILABLE: 3-times-a-week Glatopa 40mg/mL1,2

Also available: Once-daily Glatopa 20mg/mL

BE PART OF GENERATION G


Glatopa: a generic glatiramer acetate with an identity all its own. 

When it’s time for a generic treatment for relapsing-forms of MS—go Glatopa. Glatopa is the first FDA-approved substitutable generic glatiramer acetate, and it's made in the USA. Patients taking Glatopa are backed by GlatopaCare, which provides free, ongoing individualized support—whether they’re new to glatiramer acetate or making a switch. And it’s all provided by Sandoz, a Novartis Division, known for high-quality generics.1,3,4


When treating relapsing-forms of MS, go Glatopa

  • FDA approved as a substitutable generic that is therapeutically equivalent to Copaxone® 1,2
  • Free, ongoing individualized patient support services available through GlatopaCare
  • Dosing options include the new 3-times-a-week 40mg/mL dose and a once-daily 20mg/mL dose2
  • Made in the USA5

ENCOURAGE YOUR PATIENTS TO ENROLL IN GLATOPACARE TODAY

Free, individualized support services for your patients, including 24/7 nurse support.

Eligible* patients may pay $0 Co-Pay per month for their Glatopa 40mg/mL or 20mg/mL prescription.

View eligibility details below

GlatopaCare Representatives help patients understand their insurance benefits and can help determine the most convenient way for patients to receive Glatopa.  

Patients receive a free Glatopaject injection device when they enroll in GlatopaCare. Nurse Trainers provide support, guidance, and 1-on-1 injection training in your patients' home or by phone. 

GlatopaCare Nurses are available day or night to answer questions and provide guidance about self-injection and proper injection technique.

Encourage your patients to enroll in GlatopaCare today

Patients can enroll by calling (1.855.452.8672)

or at glatopa.com/enroll

Glatopa Co-Pay Program Eligibility

The Glatopa Co-Pay Program provides up to $9,000 in annual Co-Pay support for Glatopa prescriptions. This program is not health insurance. This program is for insured patients only; uninsured cash-paying patients are not eligible. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Card may not be combined with any other rebate, coupon, or offer. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

Glatopa Indication and Important Safety Information

Indication

Glatopa® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing-forms of multiple sclerosis.

Important Safety Information

Glatopa® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of glatiramer acetate injection 20mg/mL patients vs. 4% of those on placebo, and approximately 2% of glatiramer acetate injection 40mg/mL patients vs. none on placebo experienced a constellation of symptoms that may occur within minutes after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of glatiramer acetate injection 20mg/mL patients vs. 6% of placebo patients, and approximately 2% of glatiramer acetate injection 40mg/mL patients vs. 1% on placebo. While some episodes of chest pain occurred in the context of the immediate post-injection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy. 

Because glatiramer acetate can modify immune response, it may interfere with immune functions. For example, treatment with glatiramer acetate may interfere with recognition of foreign antigens in a way that would undermine the body’s tumor surveillance and its defenses against infection. There is no evidence that glatiramer acetate does this, but there has not been a systematic evaluation of this risk.

The most common adverse reactions with glatiramer acetate injection 20mg/mL vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%). The most common adverse reactions with glatiramer acetate injection 40mg/mL vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of glatiramer acetate injection. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with glatiramer acetate than placebo.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Glatopa.

References:

1. Sandoz. Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis [press release]. February 13, 2018. Sandoz website. https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis. Accessed February 13, 2018. 2. Glatopa [prescribing information]. Princeton, NJ: Sandoz Inc.; 2018. 3. US Department of Health and Human Services. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 4. FDA approves first generic Copaxone to treat multiple sclerosis [press release]. April 16, 2015. US Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm443143.htm. Accessed November 29, 2016. 5. Multiple Sclerosis Association of America. Press Release. Glatopa™ (glatiramer acetate injection) approved for the long-term treatment of relapsing forms of MS. Available at http://mymsaa.org/news/glatopa-approved/. Accessed November 30, 2016.

Glatopa, GlatopaCare, and Glatopaject are registered trademarks of Novartis AG.

Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd.

©2018 Sandoz Inc., a Novartis Division, 100 College Road West, Princeton, NJ 08540. All Rights Reserved.

S-GLA-1339521 02/2018